The Trump administration Department of Justice says women and babies whose lives and safety are threatened by popular abortion pills should have to wait until after U.S. Food and Drug Administration’s review of the popular abortion drug mifepristone to get relief.
The DOJ is redirecting its demands for a court-mandated pause on abortion pill lawsuits from the landmark Louisiana v. FDA case to take aim at Texas and Florida for challenging the FDA’s 2000 approval of mifepristone and subsequent expansions. It is under the Biden administration’s 2023 radical mifepristone permissions that anyone in any state can order mail-order pregnancy-ending pills and complete at-home abortions without medical oversight.
